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Summary
Purpose: 5-Fluoro-Pyrimidinone (5FP) is an oral pro-drug of 5-Fluorouracil (5FU), and is converted to 5FU by
hepatic aldehyde oxidase. Preclinically, 5FP demonstrated anti-tumor activity against colon 38 and P 388 leukemia
models in mice. Using an accelerated titration trial design with one patient cohorts and initial 100% escalations, a
Phase I trial was conducted to determine the maximum tolerated dose (MTD) of 5FP and describe its toxicity and
pharmacokinetic profile.
Patients and methods: 5FP was administered orally once daily for 5 days every 4 weeks. The initial dose
level was 23 mg/m2/d. Using single patient cohorts, escalation proceeded according to accelerated titration 4B
design, initially by 100% and subsequently 30–35% escalations (exact escalation determined by pill size) until
dose limiting toxicity was observed. A total of 19 patients were enrolled with a median age of 56 years and median
performance status of 1. Most patients were heavily pre-treated with chemotherapy, radiation therapy, or both, and
patient population included a wide variety of tumor types.
Results: Dose escalation proceeded rapidly to 1715 mg/m2/d with the only toxicities observed being nausea
and vomiting. The large number of pills necessary at that point required a formulation change, which resulted in
appreciable hematologic toxicity. This led to rapid de-escalation of dose in subsequent patients, with the MTD
finally being determined to be 625 mg/m2/d. The DLTs observed were grade 4 neutropenia for greater than 5 days
and grade 3 anemia. Other toxicities included nausea, vomiting, fatigue, constipation and mucositis. Pharmacology
studies confirmed that 5FP was converted to 5FU in humans at all dose levels. However, the extent of conversion
decreased over the five daily treatments, but returned for the subsequent cycle. The hematologic toxicity was not
related to 5FU exposure per course.
Conclusion: 5FP is a tolerable oral outpatient therapy. Accelerated titration was an efficient way of conducting
this phase I trial. The recommended phase 2 dose is 625 mg/m2/d orally for 5 days every 28 days.
Introduction
5FU is a widely used anti-metabolite having moderate
activity in the treatment of a variety of malignancies of
epithelial origin. Since its initial synthesis by Heidel-
berger over 30 years ago, much work has been done
to elucidate its cellular pharmacology and mechanism
of action [1]. There is evidence for the entry of fluor-
ouracil into the cells via a carrier-mediated process [2].
Intracellularly, 5FU is converted to FUMP and FUTP,
and subsequently FdUMP and FdUTP. The cytotox-
icity of fluorouracil is reported to be related to several
mechanisms, including: inhibition of thymidylate syn-
thetase by FdUTP [6–8]; incorporation of FUTP into
cellular RNA [3–5]; and incorporation of FdUTP into
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cellular DNA [6,10]. The relative contribution of each
of these mechanisms to cellular toxicity is not clear.
5FP differs from 5FU chemically only in that it
lacks a keto-group at position 4 of the ring structure
(Figure 1). The keto-group is introduced when ab-
sorbed 5FP is converted to 5FU by hepatic aldelyde
oxidase [15,16].
Guo and colleagues described the pharmacology
of 5FP in BDF1 mice [16]. The oral bioavailability
of 5FP in BDF1 mice varied between 78 and 100%,
depending on dosage and dosing regimen, and the
t1/2 of 5FP was slower than that of corresponding
doses of 5FU. Clearance rate of 5FP was three-fold
greater than that of 5FU. There was rapid conver-
sion of 5FP to 5FU in vivo and steady state plasma
levels of the resulting 5FU were sustained for at least
4 hours [16]. These data suggested that orally admin-
istered 5FP may be able to mimic administration of
5FU by continuous infusion. Guo et al. also reported
that oral 5FP was active in the colon 38 and P388
leukemia models in mice indicating that conversion to
and delivery of 5FU occurs in a biologically effective
manner. They also suggested that twice the milligram
dose of 5FP must be administered to achieve the same
effects of 5FU. Toxicology studies identified that the
profiles of 5FU from 5FP were the same as 5FU alone
when administered in a dose ratio of 2:1 that achieved
equitoxicity.
Since 5FP was shown to be orally bioavailable in
animal studies, it potentially represents a convenient
method of delivery of systemic 5FU, especially for
prolonged administration schedules. In addition, since
the active drug, 5FU, is formed in the liver, the admin-
istration of 5FP may lead to higher hepatic 5FU levels
and a greater anti-tumor effect against liver metastases
or primary liver cancer. 5FP was advanced to Phase
I clinical evaluation with the following objectives: To
demonstrate 5FP is a prodrug in humans, being con-
verted to 5FU; To determine the MTD of oral 5FP
on a daily × 5, q 4 weekly schedule; To describe the
toxicity associated with 5FP administration; To char-
acterize the 5FU exposure resulting from the first and
fifth days of 5FP treatment.
Materials and methods
Patient eligibility criteria
Patients with histologically confirmed solid tumors
refractory to conventional therapy or for whom no
effective therapy was known were eligible for this
study. Eligibility criteria included: anticipated sur-
vival time of at least 12 weeks; Zubrod Performance
Status ≤2; no chemotherapy or radiotherapy within
28 days of study entry (42 days for mitomycin C or
nitrosourea); age ≥18 years; no evidence of brain
metastasis on computed tomographic scan; adequate
bone marrow reserve (WBC count ≥3,000/µL, plate-
let count ≥100,000/µL); adequate liver (serum biliru-
bin ≤1.5 mg/dL) and renal function (serum creatinine
≤1.5 mg/dL); negative pregnancy test in women of
childbearing potential; no history of malabsorption
or gastric resection; no additional coexistent med-
ical problems of sufficient magnitude to jeopardize
compliance with the study. The eligibility criteria
included no limit on the extent of prior treatment
with chemotherapy or radiotherapy including prior
5FU. The study was approved by the Wayne State
University Human Investigations Committee and was
conducted in accordance with the Declaration of Hel-
sinki. In compliance with institutional as well as Food
and Drug Administration guidelines, patients were in-
formed of potential toxicities and all provided written
consent to participate in this Phase I study.
Toxicity and response evaluation
Pre-treatment tests and measurements included a com-
plete history and physical examination. Laboratory
studies included a complete blood count (CBC) with
differential, prothrombin time, partial thromboplastin
time, electrolytes, multiphasic chemistry profile (total
protein, albumin, blood urea nitrogen, creatinine,
lactic dehydrogenase, alkaline phosphatase, calcium,
uric acid, total and direct bilirubin, serum alanine
aminotransferase), and urinalysis. Baseline chest X-
ray, electrocardiogram, and pertinent radiographic
studies for assessment of evaluable/measurable dis-
ease were also obtained. Interim history and phys-
ical examinations were performed weekly to evaluate
toxic effects. CBC was monitored weekly initially,
then twice weekly when myelosuppression was noted.
Multiphasic chemistry profile and serum electrolytes
were assessed weekly.
Tumor assessment was performed at least every 2
months, more frequently if disease progression was
suspected. Clinical responses were determined ac-
cording to the following criteria. A complete remis-
sion (CR) required total disappearance of all measur-
able lesions with no new lesions and normalization of
any elevated tumor markers for at least 4 weeks. A par-
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Figure 1. The structure of 5FP and its enzymatic conversion to 5FU by hepatic aldehyde oxidase.
tial remission (PR) required a decrease by at least 50%
in the sum of the products of the perpendicular diamet-
ers of all measured lesions without appearance of new
lesions for at least 4 weeks. Stable disease (SD) was
defined as a decrease in lesion size from 0% to <50%
lasting at least 4 weeks or a steady state not qualify-
ing for increasing disease of at least 8 weeks duration,
again without the appearance of new lesions. Progress-
ive disease (PD) was defined as an increase of at least
25% in the sum of the products of the perpendicular
diameters of all measured lesions or appearance of
new lesions.
Treatment
5FP was supplied for oral administration by Sparta
Pharmaceuticals in hard gelatin capsules containing
initially 20 mg, and 50 mg, and subsequently 100 mg
(new formulation prompted by large number of pills)
of the drug. All doses were rounded to the nearest
20 mg, and only whole capsules were administered.
The drug was administered with water (8 ounces) after
an overnight fast.
This was an open-label Phase I dose-escalation and
pharmacokinetic study of 5FP. The schedule of ad-
ministration was once daily × 5 days with a 23-day
recovery period prior to the next cycle.
The accelerated titration 4B design [18] was used.
The starting dose was 23 mg/m2/dx5. Using the 4B
accelerated titration design, each initial cohort con-
sisted of 1 patient, and dose was escalated between
patients by 100% with each new course until the first
instance of DLT (≥ grade 3 non-hematologic toxicity,
excluding nausea, vomiting, alopecia or fatigue, or
grade 4 myelotoxicity) was encountered at any course
or the second instance of any course grade 2 toxicity
of any type was encountered in any course (except
nausea, vomiting or alopecia). Thereafter, 25%–35%
increments were used until the MTD was reached.
New cohort patients were not treated until the previ-
ous patient completed the 4-week cycle. Cohort size
was expanded to 3 patients per dose level when the
second instance of any grade 2 toxicity of any type
(other than nausea, vomiting or alopecia) was ob-
served. Patients who experienced toxicity (≥ grade 2)
continued treatment at the current dose level. Patients
were de-escalated to the lower dose level if they exper-
ienced DLT with the current course. Cohort size was
expanded to 6 patients when DLT was encountered.
With 5FP, the DLT consisted of myelotoxicity, spe-
cifically > 500 neutrophils nadiring for ≥ 5 days. At
the dose level of 1715 mg/m2, the large number of
pills necessitated a formulation change. The MTD was
defined as the dose level below that which produced
drug-attributable, dose-limiting toxicity in at least 2
of a minimum of 6 patients receiving either their first
or second course of 5FP. Dose limiting toxicity was
defined as any of the following: ≥ Grade 2 neurolo-
gic, renal, or cardiac toxicity, ≥ Grade 3 other non-
hematologic toxicity (excluding alopecia, nausea and
vomiting), or Grade 4 hematologic toxicity. Toxicit-




Six to eight mL of blood was collected at pre-dose, 5
min, 10 min, 15 min, 20 min, 30 min, 45 min, 60 min,
75 min, 90 min, 120 min, 150 min, 180 min, and at
360 min after administration on days 1 and 5 of the
treatment in heparin-sodium vacutubes. Plasma was
isolated by centrifugation of the tubes for 10 min at
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2500 rpm, spiked with chlorouracil internal standard,
and stored at –20 ◦C for HPLC analysis.
Separation 5 FP and 5-FU from plasma
Both 5FP and 5FU were separated from plasma by
solid phase extraction. Briefly, a 1 mL Supelclean
LC_SCX column (Suplenco, USA) was primed with
1 mL of methanol, followed by 1 mL 0.1M of Copper
(II) solution, and finally 2 mL of 50 mM potassium
monophosphate buffer (pH 7). Three hundred µL
of plasma was loaded onto the column and washed
sequentially with 2 mL of 50 mM potassium mono-
phosphate buffer (pH 7), 2 mL of methanol, and 1 mL
ether. The prodrug (5FP), its active metabolite (5FU)
and internal standard were eluted with 700 µL of 1.8M
aqueous ammonia solution. The elute was evaporated
to dryness under a stream of nitrogen in a water bath
at 60 ◦C and reconstituted in 150 µL of distilled water
by vortexing.
Estimation of 5FP and 5FU in plasma
The concentration of 5FP and 5FU in plasma was
estimated using a high performance liquid chromato-
graphy system consisting of 501 HPLC Pump (Waters
Corporation), AS-100 autosampler systems (BioRad
Laboratories), 490E multiwavelength detector (Waters
Corporation) and Millennium32 version 3.05.01 soft-
ware. Mobile phase consisted of 50 mM potassium
monophosphate buffer (pH 7) and ran at the flow rate
of 0.8 mL per minute with detection at 216 nm. A C-
18 reverse phase column (Alltech Associates, USA)
of 250 × 4.6 mm containing 5 µm size adsorbent as
stationary phase was used. The concentrations in 50
µL of sample were determined by back extrapolation
to standard curves relating increasing 5FU and 5FP to
5CU (I.S.) ratios and detector response. To minimize
degradation, the autosampler was cooled to 4 ◦C and
column was maintained at 15 ◦C.
Data analysis
Peak plasma concentration of 5FP and 5FU on days
1 and 5 were determined by direct measurement. Us-
ing WinNonlinTM, version 1.5 (Scientific Consulting,
Inc.), the area under the curve (AUC) was determined
assuming a simple compartmental model.
Results
Patient characteristics are shown in Table 1. A total of
19 patients were enrolled on the trial. These patients
Table 1. Patient characteristics
Characteristic Number
Total No. 19
Median age 56 (44–76)
















Table 2. Patients on each dose level of 5FP
Dose New patients Escalated De- Courses
(mg/m2/d) escalated
23 1 0 1
28.7 1 1 2
56 1 1 2
112 1 2 3
224 1 1 2
400 1 1 2
500 2 1 3
625 7(7 nf)∗ 2(1 of, 1 nf) 19
875 3(3 nf) 2(1 of, 1 nf) 2(2 nf) 7
1225 1(1 nf) 1(1 of) 2
1715 0 2(1 of, 1 nf) 2
∗nf: new dose formulation of the drug; of: old formulation (required
large number of pills)
had a variety of tumor types, and most of them were
heavily pretreated. The number of patients on each
dose level of 5FP are shown in Table 2. The majority
of patients completed at least one cycle of drug. The




Myelosuppression (neutropenia) was the dose limiting
toxicity in this study. The hematologic toxicity is dis-
played in Table 3. Patients at dose levels 23 mg/m2
through 500 mg/m2 tolerated the drug very well
without appreciable toxicity. Patient # 6 was entered
in the study at the dose of 400 mg/m2. Since he tol-
erated it well, it was escalated to 500 mg/m2, then
to 625, 875, 1225, and 1715 mg/m2. At this point he
only experienced nausea and vomiting. The adminis-
tration of a large number of pills at this dose forced a
change in dosage of the capsules. The dose per cap-
sule was changed from 50 mg to 100 mg hard gelatin
capsules. He was begun on the new formulation at
the 1715 mg/m2 dose. The patient was hospitalized
and experienced grade 4 neutropenia and leukopenia,
grade 3 anemia, grade 1 thrombocytopenia and mucos-
itis, grade 4 nausea and vomiting and grade 1 diarrhea
at this dose. Although some may argue that this tox-
icity was cumulative, myelosupression was also ob-
served when his dose was de-escalated, as well as in
novel patients treated at both the 1225 and 875 mg/m2
dose with the new formulation. There was no sugges-
tion of such myelotoxicity in any patient treated with
the old formulation. He subsequently underwent de-
escalation to the dose of 875 mg/m2 with the main
toxicities at this dose being grade 4 neutropenia, grade
2 anemia, grade 2 nausea and vomiting, and grade
2 fever. When new capsules were administered, the
number of administered capsules was reduced by at
least half. When wet, the capsules tend to stick to-
gether due to the gelatin that forms the outer core of
the capsule. This may result in slower drug release in
the gastrointestinal tract. Reduction of the number of
capsules (as a result of increased capsule size), will
minimize this effect resulting in quicker drug release
followed by faster absorption. In vitro dissolution
studies usually do not predict these events as standard
dissolution testing is performed using 10 capsules in
1000 mL of simulated gastric fluid. Other toxicities
experienced with this new formulation (875 mg/m2)
included grade 4 neutropenia (2 pts.), grade 3 leuko-
penia (2 pts.), grade 1 thrombocytopenia (1 pt.), grade
2 constipation (1 pt.), grade 1 nausea (1 pt.) and grade
2 vomiting (2 pts.). At the 625 mg/m2 dose, maximum
toxicity was grade 2 (Table 3, 4). The MTD with this
new formulation was determined to be 625 mg/m2/d.
At this dose level, there were no admissions for
neutropenic fever or sepsis, and none of the patients
required platelet transfusions. One patient was admit-
ted for nausea and vomiting secondary to small bowel
obstruction (thought possibly due to capsule bezoar).
There were no deaths from treatment in the study.
Other toxicities
Table 4 illustrates the non-hematologic toxicities ob-
served with 5 FP. The main toxicities were gastro-
intestinal including nausea, vomiting, diarrhea, con-
stipation, fatigue and mucositis. Most of these toxicit-
ies were mild except for nausea and vomiting which
were grade 4 in 1 patient.
Pharmacokinetic results
Of the 19 patients investigated in the study, pharma-
cokinetic analysis was possible in 11 patients in the
dose range of 500 mg/m2 to 1225 mg/m2. Treatment
was discontinued in the remaining patients due to pro-
gression of the disease and not associated with drug
administration. The data suggested that all the patients
converted 5FP to 5FU on days 1 and 5 of therapy, and
hence 5FP is a prodrug of 5FU (Table 5). Based on
the sum of 5FP plus 5FU AUCs, increasing the 5FP
dose increased the amount of absorbed drug (Figure 2,
Table 5). However, the AUC of 5FU is highly vari-
able and at times did not increase proportionally with
an increase in dose (Figure 2c and 2d). Further, 5FU
AUC was considerably lower and averaged 1500 µM-
min on day 5 at all administered doses (Figure 2d,
Table 6). Drug related hematotoxicity (neutropenia)
observed out to 5 cycles did not correlate with Cpmax
(Figure 3) or AUC of either 5-FP or 5-FU (data not
shown).
Discussion
5FU remains one of the most commonly used agents
for the treatment of a variety of neoplastic disorders
and is used in a variety of schedules [11–14]. When
given as a bolus dose, the doses range from 300 to
450 mg/m2/d intravenously for five days every 28
days or 600 to 750 mg/m2 intravenously weekly or
every other week. Infusional 5FU has also been used
extensively in schedules ranging from 1g/m2/d for
4–5 days to prolonged infusions at the doses of 200–
300 mg/m2/d. Although higher response rates have
been observed with continuous infusion 5FU, none of
the different schedules have impacted survival [14].
This phase I study reports the first clinical ex-
perience with 5FP, which is a rationally designed
oral fluoropyrimidine, converted to 5FU by hepatic
aldehyde-oxidase. It offers an advantage over 5FU in
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Table 3. Incidence of hematologic toxicity
Adverse events Dose level (mg/m2/d)a
625 875 1225 1715
N=9∗ N=7∗ N=2∗ N=2∗
Grade Grade Grade Grade Grade Grade Grade Grade
1–2 3–4 1–2 3–4 1–2 3–4 1–2 3–4
Anemia 1 0 1 1 1 0 0 1
Thrombocytopenia 0 0 1 0 0 0 1 0
Neutropenia 1 0 0 2 0 1 0 1
apatients at dose-levels 23 mg/m2
through 500 mg/m2 did not experience
significant toxicity ∗N = number of patients per dose level
Table 4. Incidence of non-hematologic toxicity
Adverse events Dose level (mg/m2/d)a
625 875 1225 1715
N=9∗ N=7∗ N=2∗ N=2∗
Grade Grade Grade Grade Grade Grade Grade Grade
1–2 3–4 1–2 3–4 1–2 3–4 1–2 3–4
Nausea 6 1 4 0 1 0 2 0
Vomiting 3 1 3 0 0 0 2 0
Fatigue 4 0 4 0 0 0 1 0
Constipation 2 0 2 0 1 0 1 0
Diarrhea 4 0 0 0 0 0 0 0
Mucositis 3 0 0 0 1 0 1 0
apatients at dose-levels 23 mg/m2
through 500 mg/m2 did not experience
significant toxicity; ∗N= total number
of patients per dose level
Table 5. 5-FP to 5-FU conversion on day 1 of cycle 1
Administered Total 5FU Ratio of
dose No. of AUC∗ AUC 5-FU AUC: % Prodrug
(mg/m2/d) patients (mM-min) ± Stdev (mM- ± Stdev 5-FP AUC converters
min)
500 1 1565 987 1.7 100
625 6 6660 ± 6586 2049 ± 1852 0.44 100
875 3 21872 ± 18110 3208 ± 1111 0.17 100
1225 1 87498 651 0.0075 100
∗Total AUC is the sum of 5 FP and 5 FU AUCs
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Table 6. 5-FP to 5-FU conversion on day 5 of cycle 1
Administered Total 5FU Ratio of
dose No. of AUC∗ AUC 5-FU AUC: % Prodrug
(mg/m2/d) patients (mM-min) ± Stdev (mM- ± Stdev 5-FP AUC converters
min)
500 1 4565 1097 0.32 100
625 6 19153 ± 16744 1420 ± 928 0.08 100
875 3 52600 ± 21487 1005 ± 761 0.02 100
1225 1 78059 1302 0.017 100
∗Total AUC is the sum of 5 FP and 5 FU AUCs
Figure 2a. Relationship between administered dose and total sys-
temic exposure (5FP AUC plus 5FU AUC), indicating that increas-
ing dose increased amount of absorbed drug. Measurement made
in Cycle 1 on Day 1 (a) and day 5 (b) of treatment. Relationship
between administered dose and systemic exposure to 5FU. Note that
5FU exposure was considerably less on day 5 (d) than day 1 (c).
that it can be administered in a more convenient out-
patient format compared to intravenous 5FU. More
importantly, since the active drug, 5FU, is formed
in the liver, the administration of 5FP may lead to
higher hepatic 5FU levels and a greater anti-tumor
effect against liver metastases or primary liver cancer.
The dose limiting toxicity with 5FP was my-
elosuppression (Table 3). Other toxicities observed
were gastrointestinal (nausea, vomiting, constipation,
diarrhea, and mucositis – Table 4), and fatigue. There
were no cases of hand-foot syndrome. This toxicity
profile is similar to that seen with bolus administration
of 5FU. The myelosuppression was readily reversible
prior to the next cycle (no treatment delays) and pa-





of the drug. At the MTD (625 mg/m2/d), a total of 19
courses of drug were administered among 9 patients.
No responses were observed in this trial except for a
minor response in a patient with thymoma. The max-
imum tolerated dose was identified as 625 mg/m2/d
orally for 5 days every 28 days. This dose is also the
recommended phase 2 dose.
Pharmacokinetic studies confirmed that 5FP was
absorbed and detectable levels were achieved in
plasma. Also, 5FP conversion to 5FU was evident both
on the first and fifth days of treatment at all dose levels
(Tables 5 and 6). The extent of 5FP conversion to 5FU
decreased over the five days as evident from the ra-
tios of 5FP AUC to 5FU AUC (Table 5 and 6), but
recovered by day one of the subsequent cycle, sug-
gesting adverse drug effects on the activating enzyme
that reversed within 23 days of therapy (before the
subsequent cycle). This decrease suggests saturation
of aldehyde oxidase as the 5FP dose is increased. At
each dose level, lower relative conversion of 5FP to
5FU was observed after 5 days of treatment, suggest-
ing further that the enzyme remains saturated with the
higher 5FP AUCs achieved on day 5. Consequently,
5FU exposure achieved did not increased proportion-
ally with increase in dose as shown in Figure 2. The
hematologic toxicity did not seem to be related either
to the 5FP or 5FU peak plasma concentration, since
even some of the lowest exposures were associated
with grade 4 toxicity and vice-versa (Figure 3). Accel-
erated titration 4B trial design (rapid intra-patient drug
dose escalation) was followed in this trial. We believe
Figure 3. Lack of relationship between grade of neutropenia and
peak plasma concentration of 5FP or 5FU (all courses).
that this was an efficient way of escalating the dose of
5FP in this trial. This design proved safe and reduced
the number of patients who were under treated, sped
the completion of the trial and provided a substantial
increase in the amount of information obtained. Had a
3 patient cohort modified Fibonacci design been used,
a minimum of 14 dose levels and 45 patients would
have been needed to achieve the same endpoint. In
this study, a total of 19 patients and 11 dose levels
completed accrual. The initial overshoot of the doses
beyond that which caused grade 3/4 toxicity was not
due to the accelerated titration design, but rather due
to the change in formulation.
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